Ratings by Wolfe Research (Rudy Li)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/15/2026 | Ovid Therapeutics Inc | OVID | New Coverage | Outperform (N/A) |
2.19 (2.16) |
-1.37% | Details | |
| 10/15/2026 | Bright Minds Biosciences Inc. | DRUG | New Coverage | Outperform (N/A) |
50.71 (52.48) |
3.49% | Details | |
| 10/15/2026 | Rapport Therapeutics | RAPP | New Coverage | Outperform (N/A) |
28.33 (25.93) |
-8.47% | Details | |
| 8/26/2026 | Harmony Biosciences Holdings Inc. | HRMY | New Coverage | Outperform (N/A) |
38.95 (36.13) |
-7.24% | Details | |
| 7/29/2026 | uniQure BV | QURE | Upgrade | Outperform (Peerperform) |
36.66 (22.43) |
-38.82% | Details | |
| 7/27/2026 | MapLight Therapeutics | MPLT | Maintain | Outperform (N/A) |
|
Details | ||
| 7/7/2026 | Compass Pathways | CMPS | Maintain | Outperform (N/A) |
|
Details | ||
| 7/7/2026 | LB Pharmaceuticals Inc | LBRX | New Coverage | Outperform (N/A) |
33.41 (38.73) |
15.92% | Details | |
| 5/22/2026 | Alto Neuroscience | ANRO | New Coverage | Outperform (N/A) |
21.54 (21.97) |
2% | Details | |
| 5/22/2026 | Compass Pathways | CMPS | New Coverage | Outperform (N/A) |
11.59 (11.18) |
-3.54% | Details | |
| 5/22/2026 | Immunic Inc. | IMUX | New Coverage | Outperform (N/A) |
12.30 (7.41) |
-39.76% | Details | |
| 3/31/2026 | Centessa Pharmaceuticals | CNTA | Downgrade | Peerperform (Outperform) |
27.58 (40.50) |
46.85% | Details | |
| 2/24/2026 | uniQure BV | QURE | New Coverage | Peerperform (N/A) |
23.43 (36.66) |
56.47% | Details | |
| 2/24/2026 | Stoke Therapeutics | STOK | New Coverage | Outperform (N/A) |
34.29 (25.04) |
-26.98% | Details | |
| 2/24/2026 | Xenon Pharmaceuticals | XENE | New Coverage | Outperform (N/A) |
42.23 (35.34) |
-16.32% | Details | |
| 2/24/2026 | Axsome Therapeutics | AXSM | New Coverage | Outperform (N/A) |
183.72 (145.04) |
-21.05% | Details | |
| 2/24/2026 | Neurocrine Bio. | NBIX | New Coverage | Outperform (N/A) |
128.63 (142.70) |
10.94% | Details | |
| 2/24/2026 | Praxis Precision Medicines Inc. | PRAX | New Coverage | Outperform (N/A) |
335.28 (252.96) |
-24.55% | Details | |
| 2/24/2026 | Acadia Pharmaceuticals | ACAD | New Coverage | Outperform (N/A) |
23.99 (19.73) |
-17.76% | Details | |
| 2/24/2026 | Denali Therapeutics Inc. | DNLI | New Coverage | Peerperform (N/A) |
20.19 (18.41) |
-8.82% | Details | |
| 2/24/2026 | Alkermes | ALKS | New Coverage | Outperform (N/A) |
31.91 (43.63) |
36.73% | Details | |
| 2/24/2026 | Centessa Pharmaceuticals | CNTA | New Coverage | Outperform (N/A) |
24.50 (27.58) |
12.57% | Details | |
| 2/23/2026 | Definium Therapeutics Inc | DFTX | New Coverage | Outperform (N/A) |
17.13 (35.67) |
108.23% | Details |
